

Single cell massbased biomarkers for functional precision medicine

Keith L. Ligon MD PhD

Investigator, Dana-Farber Cancer Institute Chief of Neuropathology, MassGeneralBrigham (BWH)

Associate Professor, Harvard Medical School Associate Member, Broad Institute 26 September 2024 Technologies Session



Disclosures

- Travera Inc.
- BMS
- Servier
- Blaze Bioscience
- LEK
- Integragen

- founder, consultant, equity holder
 - consultant, research support

consultant

consultant

consultant consultant






Functional precision medicine technologies in cancer

Fast

Slow

Next-generation functional diagnostics



Diverse FPM Technologies with wide ranging pros and cons – many may not be easy to clinically scale


Can we develop new technologies with potential for easier FDA approval and pathology lab implementation?

Wish list


- Low cell budget
- Rapid results
- High content data
- Scalable and low-touch

Friedman et al., Nat Rev Cancer (Dec 2015)

Suspended Microchannel Resonator (SMR) Technology



Cancer is....




Fundamental to growth and division is that a cell MUST accumulate nutrients (e.g. glucose) to prepare for division

Courtesy of Scott Manalis MIT


Single cell mass accumulation rate reveals growth heterogeneity within and across patient derived models

Ligon Lab Collection of GBM 3D Neurospheres/Organoids)





Nature Biotechnology 2016

Single cell mass biomarker aids prediction of MDM2i targeted therapy drug response in GBM models



Serial SMR design allows sorting and linking scRNA-seq to MAR following *ex vivo* drug treatment





Rob Kimmerling

Compare gene expression in responding and non-responding cells linked to their functional response



ARTICLE

/ncomms10220 OPEN

A microfluidic platform enabling single-cell RNA-seq of multigenerational lineages


Received 19 Jun 2015 | Accepted 17 Nov 2015 | Published 6 Jan 2016

Robert J. Kimmerling^{1,2}, Gregory Lee Szeto^{1,2,3,4,†}, Jennifer W. Li², Alex S. Genshaft^{4,5,6,7}, Samuel W. Kazer^{4,5,6,7}, Kristofor R. Payer⁸, Jacob de Riba Borrajo^{2,7}, Paul C. Blainey^{2,7}, Darrell J. Irvine^{1,2,3,4,9}, Alex K. Shalek^{4,5,6,7,10,11} & Scott R. Manalis^{1,2,12}

Single-cell Mass/MAR in Freshly Isolated CNS Tumor Samples

- IDH-mutant high-grade glioma
- IDH-wild type glioblastoma
- NSCLC
- Breast

Measurements at 18-36 hours after surgery



Real world lesson learned:

Serial assays feasible but clinical samples inherently challenging to implement due to physical clogs and debris

Seth Malinowski, Mehdi Touat, Kristine Pelton, Mark Stevens

Parallel SMR Array approach enables retrospective clinical-scale mass biomarker testing of patient models





Seth Malinowski

Mehdi Touat

Single mass snap-shot on multiple cells

Max Stockslager


AKA - Mass Blaster!

Question: Can single cell mass biomarker predict response to relevant SOC and trial drugs in GBM patient derived spheroids/organoids?

Ex vivo cell mass response predicts longer overall survival in GBM patients

Patient 1 Response

Patient 2 No Response



Capturing scDensity+Mass is achievable using in-line fluorescent imaging





MIT



Richard Wu MIT

Teemu Miettinen

Kin Hoe Chow DFCI

Wu et al *in review*

scDensity is a highly sensitive functional biomarker of lymphocyte state

Evaluation for potential I/O biomarker of response to PD1i and others agents

scDensity response in absence of detectable scMass response predicts in vivo response to chemotherapy in PDAC PDX

PDAC PDX In vivo Response

PDAC PDX

PD

PR

Future validation of screening in PDX ex vivo as "replacement" for expensive in vivo preclinical studies

Acknowledgements

Ligon Lab, DFCI Seth Malinowski Cecile Maire Mehdi Touat Mark Stevens Frederik DeSmet Samer Haidar, David Knoff Kristine Pelton Kate Schoolcraft Mehdi Touat

Brain Tumor Center, DFCI Patrick Wen Brian Alexander

Manalis Lab, MIT Richard Wu Teemu Miettinen Mark Stevens Nigel Chou Nate Cermak, Selim Olcum, Nick Calistri Sarah Ishamuddin Vivian Hecht Max Stockslager Rob Kimmerling David Weinstock Lab DFCI/Merck Mark Murakami DFCI Alex Shalek MIT

Funding and resources

BMS Koch Institute - Center for Precision Cancer Medicine Swanson Biotechnology Center DFCI Center for Patient Derived Models Ludwig Center at MIT NCI SU2C Bridge Project NCI 3000 Miles to the Cure Foundation

Patient donors and their families!